



WHO PREFERRED PRODUCT  
CHARACTERISTICS OF

**monoclonal  
antibodies  
for passive  
immunization  
against  
respiratory  
syncytial virus  
(RSV) disease**



World Health  
Organization



**WHO preferred product characteristics of monoclonal  
antibodies for passive immunization against  
respiratory syncytial virus (RSV) disease**

WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease

ISBN 978-92-4-002185-3 (electronic version)

ISBN 978-92-4-002186-0 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Lushomo

Cover photograph courtesy of WHO / Blink Media - Nana Kofi Acquah

---

# Contents

Acknowledgements . . . . .	iv
Funding . . . . .	iv
Abbreviations and glossary . . . . .	v
1. Background and purpose of WHO preferred product characteristics . . . . .	1
2. The case for prevention of RSV disease in young infants . . . . .	2
3. Context of available interventions. . . . .	3
4. Clinical development of mAbs. . . . .	4
5. WHO strategic vision for RSV mAbs . . . . .	4
6. PPCs for RSV mAbs . . . . .	5
References . . . . .	9

---

# Acknowledgements

The Department of Immunization, Vaccines and Biologicals (IVB) at the World Health Organization (WHO) would like to thank the many individuals who contributed to the development of this document.

The draft preferred product characteristics (PPCs) for respiratory syncytial virus (RSV) monoclonal antibodies (mAbs) was prepared by Daniel Feikin and Erin Sparrow, in the IVB department at WHO, with review by and contributions from a global expert working group.

This working group included: Ifedayo Adetifa (KEMRI-Wellcome Trust Research Programme, Kenya); Nathorn Chaiyakunapruk (University of Utah, USA); Thomas Cherian (MM Global Health, Switzerland); Deshayne Fell (Children's Hospital of Eastern Ontario Research Institute and University of Ottawa, Canada); Barney Graham (NIH, USA); Bruce Innis (PATH, USA); Ruth Karron (Johns Hopkins University, USA); Harish Nair

(University of Edinburgh, UK); Kathy Neuzil, (University of Maryland, USA); Samir Saha (Bangladesh Institute of Child Health, Bangladesh); Peter Smith (London School of Hygiene & Tropical Medicine, UK); Fred Were (University of Nairobi, Kenya); Heather Zar (University of Cape Town, South Africa). Declarations of any competing interests were received from all experts. WHO processes were used to assess declared interests and to manage any conflicts of interest. We also thank the several organizations and individuals who provided valuable input through public consultation on the draft of this document, which was open from 3 April to 10 May 2020. We also express our sincere thanks to the members of the WHO Product Development for Vaccines Advisory Committee ([www.who.int/immunization/research/committees/pdvac](http://www.who.int/immunization/research/committees/pdvac)) for their review.

---

## Funding

This work was supported by the Bill & Melinda Gates Foundation (BMGF) (Grant number: OPP1114766).

---

# Abbreviations and glossary

ADA	anti-drug antibodies	LMIC	low- and middle-income countries
ALRI	acute lower respiratory infection	mAb	monoclonal antibody
CHD	chronic heart disease	MA	medically attended
CLD	chronic lung disease	PPC	preferred product characteristics
DALY	disability-adjusted life-year	PQ	WHO prequalification
DTP	diphtheria, tetanus and pertussis vaccine	QALY	quality-adjusted life-year
EPI	Expanded Programme on Immunization	RCT	randomized controlled trial
ERD	enhanced respiratory disease	RSV	respiratory syncytial virus
FDA	United States Food and Drug Administration	RSV-IGIV	RSV immunoglobulin intravenous
GAVI	Gavi, the Vaccine Alliance	SAGE	WHO Strategic Advisory Group of Experts (on immunization)
IVB	Department of Immunization, Vaccines and Biologicals	WHO	World Health Organization
LRTI	lower respiratory tract infection	UN	United Nations





预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23833](https://www.yunbaogao.cn/report/index/report?reportId=5_23833)

